tetano
Editor, Senior Moderator
iScience
. 2021 Nov 17;103379.
doi: 10.1016/j.isci.2021.103379. Online ahead of print.
Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2
Junpei Ohtsuka[SUP] 1 2 3 [/SUP], Masaki Imai[SUP] 4 [/SUP], Masayuki Fukumura[SUP] 1 2 3 [/SUP], Mitsuyo Maeda[SUP] 5 6 [/SUP], Asami Eguchi[SUP] 5 6 [/SUP], Ryoichi Ono[SUP] 1 [/SUP], Tadashi Maemura[SUP] 4 7 [/SUP], Mutsumi Ito[SUP] 4 [/SUP], Seiya Yamayoshi[SUP] 4 [/SUP], Yosky Kataoka[SUP] 5 6 [/SUP], Yoshihiro Kawaoka[SUP] 4 7 8 [/SUP], Tetsuya Nosaka[SUP] 1 2 [/SUP]
Affiliations
Abstract
We developed an intranasal vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the replication-incompetent human parainfluenza virus type 2 (hPIV2) vector BC-PIV, which can deliver ectopic gene as stable RNA and ectopic protein on the envelope. BC-PIV expressing the full-length prefusion-stabilized spike gene (K986P/V987P) of SARS-CoV-2, S-2PM, possessed a corona-like viral envelope. Intranasal vaccination of mice with BC-PIV/S-2PM induced high levels of neutralizing immunoglobulin G (IgG) and mucosal IgA antibodies against the spike protein. Although BC-PIV showed hemagglutinating activity, BC-PIV/S-2PM lacked such activity, in accordance with the presence of the massive spike protein on the viral surface. Furthermore, single-dose intranasal vaccination of hamsters with BC-PIV/S-2PM completely protected the lungs from SARS-CoV-2 at 11-week post-immunization, and boost vaccination two weeks before the challenge conferred virtually complete protection of the nasal turbinates against SARS-CoV-2. Thus, this chimeric hPIV2/spike intranasal vaccine is a promising vaccine candidate for SARS-CoV-2 to curtail virus transmission.
Keywords: Infection control in health technology; Virology.
. 2021 Nov 17;103379.
doi: 10.1016/j.isci.2021.103379. Online ahead of print.
Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2
Junpei Ohtsuka[SUP] 1 2 3 [/SUP], Masaki Imai[SUP] 4 [/SUP], Masayuki Fukumura[SUP] 1 2 3 [/SUP], Mitsuyo Maeda[SUP] 5 6 [/SUP], Asami Eguchi[SUP] 5 6 [/SUP], Ryoichi Ono[SUP] 1 [/SUP], Tadashi Maemura[SUP] 4 7 [/SUP], Mutsumi Ito[SUP] 4 [/SUP], Seiya Yamayoshi[SUP] 4 [/SUP], Yosky Kataoka[SUP] 5 6 [/SUP], Yoshihiro Kawaoka[SUP] 4 7 8 [/SUP], Tetsuya Nosaka[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34805782
- PMCID: PMC8596570
- DOI: 10.1016/j.isci.2021.103379
Abstract
We developed an intranasal vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the replication-incompetent human parainfluenza virus type 2 (hPIV2) vector BC-PIV, which can deliver ectopic gene as stable RNA and ectopic protein on the envelope. BC-PIV expressing the full-length prefusion-stabilized spike gene (K986P/V987P) of SARS-CoV-2, S-2PM, possessed a corona-like viral envelope. Intranasal vaccination of mice with BC-PIV/S-2PM induced high levels of neutralizing immunoglobulin G (IgG) and mucosal IgA antibodies against the spike protein. Although BC-PIV showed hemagglutinating activity, BC-PIV/S-2PM lacked such activity, in accordance with the presence of the massive spike protein on the viral surface. Furthermore, single-dose intranasal vaccination of hamsters with BC-PIV/S-2PM completely protected the lungs from SARS-CoV-2 at 11-week post-immunization, and boost vaccination two weeks before the challenge conferred virtually complete protection of the nasal turbinates against SARS-CoV-2. Thus, this chimeric hPIV2/spike intranasal vaccine is a promising vaccine candidate for SARS-CoV-2 to curtail virus transmission.
Keywords: Infection control in health technology; Virology.